Gain detailed insights into the trading activity of Congress members for Crinetics Pharmaceuticals on our government trades page. Stay updated on how elected officials are investing in CRNX.

Crinetics Pharmaceuticals - Government Trades

Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Which Characters From ‘Squid Game’ Are Set To Return In Season 2 Of The Popular Netflix Show

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CRNX

NDSN

NFLX

This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Analyst Color

Biotech

Equities

Large Cap

Health Care

Reiteration

General

NBIX

Neurocrine&#39;s Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation.

Neurocrine&#39;s Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

QuantumScape QS Stock

Mid Cap

Movers

APGE

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.

XPeng &amp; QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

Nvidia stock

Price Target

ADSK

GTLB

NVDA

SRCL

UPST

Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday

xr:d:DAFjzSNzgvg:2,j:47806933381,t:23052405

Intraday Update

BNTX

CSIQ

CVAC

FLNC

FSLR

IGMS

LOAR

MRNA

NVAX

SPWR

VIPS

WOOF

Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday

Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy &amp; safety, with plans for FDA submission in 2024.

Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here&#39;s Why

Penny Stocks

Small Cap

ACMR

AFIB

ALHC

ALPN

AUGX

BTDR

BYND

CJET

CLSK

CMTL

COIN

DCGO

DRCT

ELVN

ENVB

FUSN

GWAV

HOTH

HUYA

JOAN

LICY

MARA

MBTC

MNPR

MSTR

NCMI

OTRK

PIXY

PRSO

PRTG

SEEL

SMCI

SOUN

SPIR

STNE

SWIN

VERB

WORX

ZCAR

ZEPP

Shares of  Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.

Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

DAVA

FUFU

MNTK

VALN

U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.

National CineMedia Reports Upbeat Results, Joins Nordstrom, Core &amp; Main And Other Big Stocks Moving Higher On Tuesday

ARVN

ARWR

CLDX

DELL

EVBG

MLTX

NTAP

OPRA

PTCT

RDNT

RGNX

RMBS

ROOT

RPAY

SANA

XPOF

YMAB

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for 

Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals Inc

Management

Athene Names Louis-Jacques Tanguy Chief Financial Officer, Effective March 1, 2025

Guidance

ARDT

Ardent Health Partners Sees FY25 EPS $1.73-$2.01 Vs $1.94 Est.; Revenue $6.20B-$6.45B Vs $6.297B Est.

Beyond Meat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) sees FY2025 sales of $320.000 million-$335.000 million vs $336.01 million analyst estimate.

Beyond Meat Sees FY2025 Sales $320.000M-$335.000M vs $336.01M Est

Xperi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPER#NYSE">XPER</a>) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.23 by 69.57 percent. This is a 254.55 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $122.36 million which missed the analyst consensus estimate of $123.89 million by 1.23 percent. This is a 10.84 percent decrease over sales of $137.23 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

XPER

Xperi Q4 Adj $0.39 Beats $0.23 Estimate, Sales $122.36M Miss $123.89M Estimate

Energy Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERII#NASDAQ">ERII</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.38 by 31.58 percent. This is a 28.21 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $67.08 million which missed the analyst consensus estimate of $67.27 million by 0.29 percent. This is a 17.29 percent increase over sales of $57.19 million the same period last year.

ERII

Energy Recovery Q4 Adj EPS $0.50 Beats $0.38 Estimate, Sales $67.08M Miss $67.27M Estimate

WIIM

RRGB

Red Robin Gourmet Burgers shares are trading higher following a Q4 revenue beat.

Talos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.02) by 500 percent. This is a 900 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $485.19 million which missed the analyst consensus estimate of $491.06 million by 1.20 percent. This is a 26.04 percent increase over sales of $384.96 million the same period last year.

TALO

Talos Energy Q4 Adj $0.08 Beats $(0.02) Estimate, Sales $485.19M Miss $491.06M Estimate

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.62 by 0.62 percent. This is a 0.61 percent decrease over earnings of $1.64 per share from the same period last year. The company reported quarterly sales of $215.00 million which missed the analyst consensus estimate of $237.84 million by 9.60 percent. This is a 16.01 percent increase over sales of $185.34 million the same period last year.

Chesapeake Utilities Q4 Adj $1.63 Beats $1.62 Estimate, Sales $215.00M Miss $237.84M Estimate

Beyond Meat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.44) by 47.73 percent. This is a 29.35 percent increase over losses of $(0.92) per share from the same period last year. The company reported quarterly sales of $76.66 million which beat the analyst consensus estimate of $75.31 million by 1.80 percent. This is a 4.04 percent increase over sales of $73.68 million the same period last year.

Beyond Meat Q4 Adj $(0.65) Misses $(0.44) Estimate, Sales $76.66M Beat $75.31M Estimate

Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) Q1 expected Adj EPS to be more than $(0.07) vs $(0.01) Est. sees Q1 sales of $94.000 million-$104.000 million vs $98.53 million analyst estimate.

AAOI

Applied Optoelectronics Q1  expected Adj EPS to be more than $(0.07) vs $(0.01) Est; Sees Q1 Sales $94.000M-$104.000M vs $98.53M Est

Innoviva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVA#NASDAQ">INVA</a>) reported quarterly earnings of $0.26 per share which missed the analyst consensus estimate of $0.37 by 29.73 percent. This is a 65.79 percent decrease over earnings of $0.76 per share from the same period last year. The company reported quarterly sales of $91.81 million which beat the analyst consensus estimate of $86.80 million by 5.77 percent. This is a 6.95 percent increase over sales of $85.84 million the same period last year.

INVA

Innoviva Q4 EPS $0.26 Misses $0.37 Estimate, Sales $91.81M Beat $86.80M Estimate

CPOP

Pop Culture Group shares are trading higher after the company announced it closed the acquisition for the equity interest in Xiamen Hand In Hand Network Technology.

Ardent Health Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARDT#NYSE">ARDT</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.44 by 84.09 percent. The company reported quarterly sales of $1.610 billion which beat the analyst consensus estimate of $1.484 billion by 8.48 percent.

Ardent Health Partners Q4 2024 GAAP EPS $0.81 Beats $0.44 Estimate, Sales $1.610B Beat $1.484B Estimate

<img alt="AI, Artificial Intelligence concept,Technology background. Central Computer Processors CPU Tech science background. Integrated communication processor." class="article-image-one" src="https://www.marketbeat.com/logos/articles/med_20250221101313_3-stocks-poised-to-thrive-as-nvidia-dominates-the.jpg" style="height:643px; width:1200px" />
Everyone knows that&nbsp;<a href="https://www.marketbeat.com/stocks/NASDAQ/NVDA/">NVIDIA Co. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) is the leader in the <a href="https://www.marketbeat.com/stocks/sectors/computer-and-technology/">technology sector</a> and its race to provide the necessary components for <a href="https://www.marketbeat.com/compare-stocks/artificial-intelligence-stocks/">artificial intelligence</a> to grow into what most investors think it could be. However, this doesn&#39;t mean that investors need to only pay attention to NVIDIA but rather zoom out into some of the other less crowded ideas out there.
Moving across the artificial intelligence value chain can be a great start, but of course, we should always keep NVIDIA&#39;s success in mind. Through this, investors can land on areas like components makers that enable NVIDIA to make their industry-leading graphic processing units (GPUs), the companies that focus on data centers relying on these very chips, and even the cloud computing businesses in the market, which can only operate using this sort of technology.
These reasons are exactly why investors should keep an eye on names like <a href="https://www.marketbeat.com/stocks/NYSE/TSM/">Taiwan Semiconductor Manufacturing (NYSE: </a><a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>), <a href="https://www.marketbeat.com/stocks/NASDAQ/AVGO/">Broadcom Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/avgo#NASDAQ">AVGO</a>), and even <a href="https://www.marketbeat.com/stocks/NASDAQ/GOOGL/">Alphabet Inc. (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) in the coming quarters. This is especially the case if these same investors believe that NVIDIA&#39;s success is far from reaching its full potential, as there might be much more upside in these lateral plays.
<h2>Taiwan Semiconductor Stock: Not Done Yet</h2>
Even though shares of Taiwan Semiconductor stock already trade within <a href="https://www.marketbeat.com/stocks/NYSE/TSM/chart/">90% of their 52-week highs</a>, one fundamental driver still pushes for more upside behind this name&mdash;one investors should pay attention to in the coming quarters.
[content-module:Forecast|NYSE:TSM]
Considering that earnings per share (EPS) typically drive stock price performance, investors should note that Wall Street now <a href="https://www.marketbeat.com/stocks/NYSE/TSM/earnings/">forecasts up to $2.66 in EPS</a> for Taiwan Semiconductor stock to be delivered in the fourth quarter of 2025.
Compared to today&#39;s $2.24 EPS, that&#39;s roughly an 18.7% growth rate, which should drive the stock higher.
Knowing that Taiwan Semiconductor stock&#39;s outlook is set for a bullish EPS path ahead, it shouldn&#39;t come as a surprise to see analysts from Barclays reiterate a buy rating on the company as of January 2025, this time keeping a <a href="https://www.marketbeat.com/stocks/NYSE/TSM/forecast/">$255 per share valuation</a>.
This new target would not only call for a new 52-week high in the stock but also for as much as a 26% upside from where it trades today, giving investors yet another reason to stick around and ride the benefits of this company being one of the main suppliers for NVIDIA&#39;s GPU manufacturing chain.
<h2>Data Centers Mix Well With Broadcom</h2>
The other aspect that will benefit from the growth of artificial intelligence is data centers, as these are the places where models are trained and developed on massive amounts of data. This mostly requires computing power delivered by NVIDIA chips. This is where Broadcom comes into play for investors to consider.
[content-module:Forecast|NASDAQ:AVGO]
Being exposed to this area of the market allows the company to carry more tailwinds behind it, and Barclays analysts have also noticed this recently in their ratings.
With an overweight rating on Broadcom, these analysts now see the company valued at a&nbsp;<a href="https://www.marketbeat.com/stocks/NASDAQ/AVGO/forecast/">high of $260 per share</a>, which, like their rating for Taiwan Semiconductor, calls for a new 52-week high along with a net upside of as much as 16% from where it trades today.
Understanding that Broadcom&#39;s path in the artificial intelligence race is relatively set, some institutional buyers were willing to take this view for themselves, such as those from the UBS Asset Management group, who boosted their holdings in Broadcom stock by as much as 1.7% over the past quarter.
This new allocation brought their net position to a <a href="https://www.marketbeat.com/stocks/NASDAQ/AVGO/institutional-ownership/">massive $7.9 billion today</a>, showing investors yet another vote of confidence coming into Broadcom stock.
<h2>Cloud Computing Is Google&#39;s Path to Higher Prices</h2>
Last but not least, cloud computing should not be forgotten in this race for artificial intelligence development, and this is exactly where Alphabet (Google) comes into play.
[content-module:Forecast|NASDAQ:GOOGL]
By having access to the world&#39;s search trends, text, video, and other forms of data, Google is able to feed artificial intelligence models what they need to compound themselves.
That&#39;s why analysts at Citigroup felt comfortable enough with the story to reiterate a buy rating on the stock while also laying out a valuation <a href="https://www.marketbeat.com/stocks/NASDAQ/GOOGL/forecast/">target of up to $229</a> per share. This is not only another new 52-week high for today&#39;s list of winners but also a net upside of as much as 25.5% from today&#39;s stock price.
It would seem that even the bearish traders, calling Google&#39;s valuation overextended, have decided that it&#39;s not worth the fight considering all of the bullish factors building up right now for the company in its artificial intelligence exposure.
Over the past month,&nbsp;<a href="https://www.marketbeat.com/stocks/NASDAQ/GOOGL/short-interest/">Google&#39;s short interest</a> declined by as much as 8.2% to show signs of bearish capitulation.
<h2><a href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink" style="text-decoration:none;color:var(--dark-blue); font-weight:500;">Where Should You Invest $1,000 Right Now?</a></h2>
Before you make your next trade, you&#39;ll want to hear this.
MarketBeat keeps track of Wall Street&#39;s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the <a href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink">five stocks</a> that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
<a class="btn btn-featured" href="https://www.marketbeat.com/newsletter/PDFoffer.aspx?offer=top5&amp;RegistrationCode=SyndicatedArticleLink" style="text-decoration:none">See The Five Stocks Here </a>
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-stocks-poised-to-thrive-as-nvidia-dominates-the-ai-boom/">3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom</a>&quot; first appeared on MarketBeat.

Tech

AVGO

GOOGL

3 Stocks Poised To Thrive As NVIDIA Dominates The AI Boom

Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. This is a 150 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $100.27 million which beat the analyst consensus estimate of $99.92 million by 0.35 percent. This is a 65.87 percent increase over sales of $60.45 million the same period last year.

Applied Optoelectronics Q4 Adj EPS $(0.02), Inline, Sales $100.27M Beat $99.92M Estimate

Sinclair Broadcast Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $1.90 by 37.37 percent. This is a 222.22 percent increase over earnings of $0.81 per share from the same period last year. The company reported quarterly sales of $1.00 billion which missed the analyst consensus estimate of $1.01 billion by 0.17 percent. This is a 21.55 percent increase over sales of $826.00 million the same period last year.

SBGI

Sinclair Broadcast Group Q4 EPS $2.61 Beats $1.90 Estimate, Sales $1.00B Miss $1.01B Estimate

CERT

Certara Sees FY25 Adj. EPS $0.42-$0.46 Vs $0.50 Est.; Revenue $415M-$425M Vs $421.956M Est.

SEMrush Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEMR#NYSE">SEMR</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01 by 100 percent. This is a 60 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $102.60 million which beat the analyst consensus estimate of $101.45 million by 1.13 percent. This is a 23.03 percent increase over sales of $83.39 million the same period last year.

SEMR

SEMrush Hldgs Q4 2024 GAAP EPS $0.02 Beats $0.01 Estimate, Sales $102.60M Beat $101.45M Estimate

LegalZoom.com shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 revenue guidance above estimates.

Honest Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNST#NASDAQ">HNST</a>) sees FY2025 sales of $393.474 million-$401.040 million vs $396.84 million analyst estimate.

HNST

Honest Co Sees FY2025 Revenue 4% to 6% from YOY, Revenue  $393.474M-$401.040M vs $396.84M Est

Press Releases

Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)


Gilbert Ray CisnerosHouse (D-CA)	$1K - $15K	stock	Purchase	Feb 11, 2025	Jan 29, 2025	House
Josh GottheimerHouse (D-NJ)	$1K - $15K	stock	Purchase	Oct 03, 2024	Sep 25, 2024	House

Government Trades

Crinetics Pharmaceuticals Inc

top performing CRNX trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga